ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1442 • ACR Convergence 2022

    Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

    Anca Askanase1, John Conklin2, Michelle Petri3, Vasileios Kyttaris4, Yevgeniya Gartshteyn5, Wei Tang1, Anja Kammesheidt6 and Roberta Alexander2, 1Columbia University Medical Center, New York, NY, 2Exagen, Inc., Vista, CA, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Columbia University Medical Center, Glen Rock, NJ, 6self, Laguna Beach, CA

    Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
  • Abstract Number: 1607 • ACR Convergence 2022

    Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis

    Vincent Bouget1, Julien Duquesne1, Paul-Henry Cournède2, Bruno Fautrel3, Francis Guillemin4, Pascal de Jong5, Judith Heutz6, Marloes Verstappen7, Annette van der Helm-van Mil8, Xavier Mariette9 and Samuel Bitoun10, 1Scienta Lab, Paris, France, 2Paris-Saclay University - CentraleSupelec, Paris, France, 3Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 4Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, 5ErasmusMC, Hendrik Ido Ambacht, Netherlands, 6Erasmus Medical Center, Rotterdam, Netherlands, 7Leiden University Medical Center, Leiden, Netherlands, 8Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 9Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 10Paris-Saclay University, Paris, France

    Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
  • Abstract Number: 1862 • ACR Convergence 2022

    Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial

    Thomas Vazquez1, Meena Sharma1, Rui Feng2, DeAnna Diaz3, Nilesh Kodali1, Josh Dan3, Madison Grinnell3, Emily Keyes3, Grant Sprow3, Barbara White4 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 4Corbus Pharmaceuticals, Pleasanton, CA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
  • Abstract Number: 1993 • ACR Convergence 2022

    Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention

    Esha Lal1, Marta Sala Climent2, francesca cedola2, Marta Fernandez-Bustamante3, Meritxell Agustín-Perez2, Maram Alharti2, Abha Singh4, Soo-In Choi2, Tania Rivera2, Katherine Nguyen4, Susan Lee2, Aaron Armando5, Tiffany Holt6, Oswald Quehenberger5, Shahrokh Golshan6, Roxana Coras7 and Monica Guma8, 1Department of Medicine, School of Medicine, University of California, San Diego, San Diego, 2Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, 3Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, 4University of California, San Diego, San Diego, CA, 5Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, 6Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, 7University of California San Diego, San Diego, CA, 8UCSD, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
  • Abstract Number: 2217 • ACR Convergence 2022

    Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

    Amir Razmjou1, Jennifer Wang1, Ani Shahbazian1, Jeffrey Curtis2, Dimitrios Pappas3, Joel Kremer4 and Christina Charles-Schoeman5, 1UCLA Medical Center, Los Angeles, CA, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
  • Abstract Number: 0248 • ACR Convergence 2022

    Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

    Veronica Pulito-Cueto1, Sara Remuzgo-Martinez1, Fernanda Genre1, Belén Atienza-Mateo1, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Leticia Lera-Gómez1, Diana Prieto-Peña1, Virgi Portilla1, Ricardo Blanco2, Alfonso Corrales1, Oreste Gualillo3, José M. Cifrián1, Raquel Lopez Mejias4 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
  • Abstract Number: 0491 • ACR Convergence 2022

    Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis

    Despina Michailidou1, Bhargavi Duvvuri1, Runa Kuley1, David Cuthbertson2, Peter Grayson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Larry Moreland8, Christian Pagnoux9, Philip Seo10, Ulrich Specks11, Antoine Sreih7, Kenneth J. Warrington11, Tomas Mustelin1, Paul Monach12, Peter Merkel13 and Christian Lood1, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of South Florida, Tampa, FL, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, 5Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, 6Cleveland Clinic, Cleveland, OH, 7Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 8University of Colorado, Denver, CO, 9Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 10Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12VA Boston Healthcare System, Boston, MA, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
  • Abstract Number: 0643 • ACR Convergence 2022

    Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare

    Mary Horton1, Joanne Nitithalm2, Kimberly Taylor3, Laura Trupin4, Patricia Katz5, Jinoos Yazdany6, Maria Dall'Era7, Lisa Barcellos8, Lindsey Criswell9 and Cristina M Lanata10, 1NIH/NHGRI, Oakland, CA, 2NIH/NHGRI, Bethesda, MD, 3University of Californi, San Francisco, San Francisco, CA, 4UC San Francisco, San Francisco, CA, 5UCSF, San Rafael, CA, 6UCSF, San Francisco, CA, 7University of California, Division of Rheumatology, San Francisco, CA, 8School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, 9National Human Genome Research Institute, NIH, Bethesda, MD, 10NIH/NHGRI, Washington, DC

    Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…
  • Abstract Number: 0889 • ACR Convergence 2022

    Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis

    Joshua Baker1, Katherine Wysham2, Bryant England3, Punyasha Roul4, Aleksander Lenert5, Grant Cannon6, Brian Sauer7, Geoffrey Thiele3 and Ted Mikuls8, 1University of Pennsylvania, Philadelphia, PA, 2VA Puget Sound/University of Washington, Seattle, WA, 3University of Nebraska Medical Center, Omaha, NE, 4UNMC, Omaha, NE, 5University of Iowa, Iowa City, IA, 6Retired, Salt Lake City, UT, 7Salt Lake City VA/University of Utah, Salt Lake City, UT, 8Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Adipokines are fat and muscle-secreted protein hormones that regulate metabolism. Adiponectin has been associated with fracture in the general population while the role of…
  • Abstract Number: 1149 • ACR Convergence 2022

    A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies

    Alejandro Durán-Sotuela1, Mercedes Fernández-Moreno1, Tamara Hermida-Gómez1, Sara Relaño1, Victoria Suárez-Ulloa2, vanesa Balboa-Barreiro3, Natividad Oreiro1, Jorge Vázquez-García1, FJ Blanco1 and Ignacio Rego-Pérez1, 1Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, 2Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, 3Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain

    Background/Purpose: Knee osteoarthritis progression is heterogeneous in the population, being the most aggresive form the rapid progressive knee osteoarthritis (RPKOA). These patients suffer a worsening…
  • Abstract Number: 1462 • ACR Convergence 2022

    Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis

    Samar Soliman1, Samantha Stanley2, Kamala Vanarsa2, Faten Ismail3, Chi Chiu Mok4 and Chandra mohan5, 1Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, 2Department of Biomedical Engineering, University of Houston, Houston, TX, 3Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, 4Tuen Mun Hospital, Hong Kong, China, 5University of Houston, Houston, TX

    Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
  • Abstract Number: 1610 • ACR Convergence 2022

    Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?

    Solveig S. Groen1, Signe Holm Nielsen2, Anne-Christine Bay-Jensen2, Mozhgan Rasti3, Darshini Ganatra3, Katerina Oikonomopoulou3 and Vinod Chandran4, 1Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
  • Abstract Number: 1868 • ACR Convergence 2022

    B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease

    Christopher Costin1, Gabrielle Morgan2, Amer Khojah3 and Lauren Pachman4, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Umm Al-Qura University, Makkah, Saudi Arabia, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical…
  • Abstract Number: 2024 • ACR Convergence 2022

    Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach

    Silvia Fonzetti1, Francesco Ferro2, Gaetano La Rocca3, Giovanni Fulvio4, Inmaculada Concepción Navarro García5, Gianmaria Governato6, Valentina Donati7, Marta Mosca8 and Chiara Baldini4, 1Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, 4University of Pisa, Pisa, Pisa, Italy, 5Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 6Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, 7Pathology Unit, University of Pisa, Pisa, Italy, 8Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
  • Abstract Number: 2223 • ACR Convergence 2022

    Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

    Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Ellen Iacobaeus1, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2, Guillermo Barturen2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 109
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology